Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05137262
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05112536
- Locations
- 🇺🇸
UCLA Department of Medicine - Hematology/Oncology, Santa Monica, California, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 927
- Registration Number
- NCT05113251
- Locations
- 🇹🇭
Research Site, Khon Kaen, Thailand
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 10
- Registration Number
- NCT05100628
- Locations
- 🇺🇸
Site name Washington University School of Medicine in Saint Louis, Saint Louis, Missouri, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Mayo Clinic Florida - Oncology, Jacksonville, Florida, United States
Lurbinectedin + Doxorubicin In Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT05099666
- Locations
- 🇺🇸
Mayo Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Jacksonville, Jacksonville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Aiping Shi
- Target Recruit Count
- 30
- Registration Number
- NCT05088057
- Locations
- 🇨🇳
Aiping Shi, Changchun, Jilin, China
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT05049473
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
🇪🇸ICO-Hospital Duran i Reynals, Bellvitge, Spain
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 185
- Registration Number
- NCT05020860
- Locations
- 🇺🇸
Harris Health System - Smith Clinic, Houston, Texas, United States
🇺🇸O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT05008224
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
🇺🇸Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇺🇸Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Czech Lymphoma Study Group
- Target Recruit Count
- 33
- Registration Number
- NCT05006664
- Locations
- 🇨🇿
University Hospital Olomouc, Olomouc, Czechia
🇨🇿University Hospital Plzeň, Plzeň, Czechia
🇨🇿University Hospital Brno, Brno, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.